Chimeric antigen receptor (CAR)-T cell therapies are becoming established as an important treatment modality for cancer. Following the pioneering approval of the CD19-targeted CAR-T therapy tisagenlecleucel by the FDA in 2017, five additional CAR-T therapies have been approved (Supplementary Fig. 1).
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Acknowledgements
The authors thank L. Almada-Sabate and J. Yim for contributions to assembling and analysing the database of CAR-T assets. They thank C. Wang for helpful suggestions on recent cell therapy data readouts. The authors thank S. Shah and D. Grossman for their contributions to understanding complexities for the cell therapy field.
Competing Interests
The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by BCG's health care practice.